Picard Medical Announces Pricing of $5 Million Offering
Picard Medical, Inc. has announced a $5 million offering of common stock and common warrants, consisting of 16,666,667 shares priced at $0.30 per share along with Series A and B Common Warrants. The offering intends to close on May 6, 2026, subject to customary conditions, and the proceeds will be used for working capital and corporate purposes, including debts.
TUCSON, Ariz., May 05, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the pricing of its “reasonable best efforts” offering with certain new and existing institutional investors for the purchase and sale of (i) 16,666,667 shares of the Company’s common stock, par value $0.0001 per share (or common stock equivalents in lieu thereof) (the “Common Stock”), (ii) series A common warrants to purchase up to 16,666,667 shares of Common Stock (the “Series A Common Warrants”), and (iii) series B common warrants to purchase up to 16,666,667 shares of Common Stock (the “Series B Common Warrants” together with the Series A Common Warrants, the “Common Warrants”) (the “Offering”). Each share of Common Stock or pre-funded warrant was sold together with an accompanying Series A and Series B Common Warrant at a combined offering price of $0.30 per share and accompanying Common Warrants. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent fees and other offering expenses payable by the Company.